Komodo Health Review 2026

B2B Contact & Company Data

Last updated: 2026-06-03

Visit Komodo Health → See All B2B Data Tools

The Bottom Line

Komodo Health is for pharma commercial and medical-affairs teams that need to understand patients and providers at the level of claims, not contacts. If you're launching a specialty or rare-disease therapy, trying to find undiagnosed patients, diagnosing why people abandon a drug, or prioritizing the providers who truly shape treatment, the Healthcare Map and its seven-signal KOL profiling give you insight no contact-data vendor can. The completeness on narrow populations is where Komodo genuinely shines.

The trade-off is that Komodo is analytics, not prospecting, and it's priced and operated like enterprise software. You'll still source verified emails and phone numbers elsewhere, you'll commit to six- or seven-figure contracts through a multi-month procurement, and you'll need analysts who can turn the platform's depth into decisions. Without that analytical capacity, the power goes underused and the cost is hard to justify.

Buy Komodo if you're a specialty or rare-disease biopharma that needs maximum data completeness on a focused patient population and has the team to exploit it. Choose IQVIA OneKey or Symphony Health when global coverage and projection-based market measurement matter more, Definitive Healthcare for broad healthcare commercial intelligence and facility data, and a per-record provider like Provyx for the actual contact details Komodo doesn't supply. Komodo owns the patient-journey-analytics lane, and that's exactly where to use it.

What is Komodo Health?

Komodo Health is a b2b contact & company data tool. Claims-based healthcare analytics platform. Komodo's real strength is patient journey mapping and treatment pattern analysis, not traditional contact data.

Best for: Pharma commercial teams that need claims-based provider targeting, not just contact info

Best For

Pharma commercial teams that need claims-based provider targeting, not just contact info

Komodo Health Overview

Komodo Health is a claims-based healthcare analytics company, and its signature asset is the Healthcare Map, a de-identified longitudinal view of more than 330 million patients in the United States. It stitches together medical and pharmacy claims from both providers and payers to follow each patient's journey across diagnoses, treatments, switches, and outcomes over time. That's a fundamentally different product from a contact-data vendor. Komodo answers 'what is happening to patients and which providers drive it,' not 'what's this doctor's email.'

For pharma commercial and medical-affairs teams, the value is patient-journey analytics. You can see where patients enter the system, how long until diagnosis, what therapies they try, where they drop off, and which providers sit at the decision points. That powers market sizing for a launch, finding undiagnosed or misdiagnosed populations, and understanding why patients abandon a therapy. Komodo's KOL profiling uses a seven-signal approach to rank provider influence, which goes well beyond simple prescribing counts.

The platform has expanded beyond raw data. Products like Patient Insights and MapEnhance let teams enrich the Healthcare Map with their own or partner data, and a recent Experian partnership adds socioeconomic and lifestyle context so teams can spot care disparities. Komodo also introduced an integrated patient-insurance dataset to sharpen patient-level analysis. The direction is clear: be the analytics layer pharma builds commercial strategy on, with AI tooling on top of the claims foundation.

Where Komodo isn't the answer: traditional sales prospecting. It won't hand you a clean list of verified emails and cell phones for cold outreach; you'll still source contact data elsewhere. It's enterprise software with custom pricing, long sales cycles, and a learning curve that rewards teams with dedicated analysts. Komodo is strongest for specialty and rare-disease biopharma where patient populations are small and data completeness matters more than breadth.

Pros & Cons

Patient-journey analytics traditional data can't matchThe Healthcare Map follows de-identified patients longitudinally across 330 million-plus records, so teams see the full arc from symptom to diagnosis to treatment to outcome. That reveals where patients get stuck, switch, or drop off, which is invaluable for therapy launches and market access. No contact-data provider offers this; it's a different category of insight built on claims, not directories.
Strong KOL and high-prescriber identificationKomodo's KOL profiling uses a seven-signal model to gauge provider influence, going far beyond prescribing volume to include factors like patient referrals, network position, and clinical activity. For medical-affairs and commercial teams, that surfaces the providers who genuinely shape treatment decisions in a therapeutic area. It's a sharper way to prioritize engagement than a flat list ranked only by script counts.
Depth and completeness for specialty and rare diseaseBecause the Healthcare Map blends provider and payer claims into one longitudinal view, it captures rare and specialty populations more completely than sample-based projections. For a biopharma launching into a small treatable population, that completeness is the difference between finding the patients and missing them. Several comparisons note Komodo outperforming projection-based vendors precisely in these narrow, high-stakes indications.
Expanding analytics and enrichment ecosystemKomodo keeps building on the data foundation with Patient Insights, MapEnhance, an integrated patient-insurance dataset, and partnerships like Experian for socioeconomic context. Teams can enrich the Healthcare Map with their own data and answer questions about care disparities and access, not just clinical patterns. The platform is moving from raw data toward a full commercial-analytics layer with AI tooling on top.

Not a contact-data providerKomodo tells you which providers matter and what's happening to patients, but it won't give you verified direct emails and cell phones for cold outreach. Sales teams expecting a prospecting list will be disappointed; you'll pair Komodo's targeting intelligence with a separate contact source like Provyx, Definitive Healthcare, or IQVIA OneKey. It's an analytics platform, and treating it like a contact database is a category mistake.
Enterprise pricing with long sales cyclesKomodo is sold through custom enterprise contracts, with reported pricing in the $150K to $450K per-use-case range and full dataset-plus-suite licensing reaching into the seven figures. There's no self-serve tier and no quick trial. Procurement is a multi-month process, which makes Komodo a deliberate strategic purchase rather than something a small team spins up to test.
Steep learning curveGetting value from the Healthcare Map and the analytics tooling rewards teams with dedicated data analysts who understand claims data and its quirks. Care to define cohorts correctly, interpret journeys, and avoid claims-data pitfalls is real work. Organizations without analytical horsepower may struggle to turn the platform's depth into decisions, and underused enterprise software is expensive shelfware.
Claims-data lag and inherent limitationsClaims data reflects what was billed and adjudicated, so there's a lag of weeks to months and gaps for cash-pay care or certain payers. The Healthcare Map is excellent for patterns and trends but isn't a real-time operational feed. Teams need to factor in that lag for launch timing and competitive monitoring, and interpret very recent activity with appropriate caution.

Use Cases

Sizing the Market for a Rare-Disease Launch

A specialty biopharma is launching a therapy for a rare condition where the treatable population might be only a few thousand patients nationwide. Using the Healthcare Map, the commercial team identifies diagnosed patients, estimates the undiagnosed pool from symptom and testing patterns, and maps where those patients receive care. The analysis shows the addressable population is concentrated among a small set of academic centers and specialists. Field and medical resources get aimed precisely at those sites from launch, avoiding the waste of broad targeting and giving leadership a defensible patient-count to plan supply and forecasting around.

Diagnosing Why Patients Abandon a Therapy

A pharma team sees disappointing persistence on an existing drug and wants to know why patients stop. Komodo's longitudinal journeys show that a meaningful share of patients drop off after a specific point, often coinciding with a side-effect-related visit or a switch prescribed by a particular provider type. With that pattern visible, the team designs targeted medical education and patient-support interventions aimed at the drop-off moment. The claims-based view turns a vague retention problem into a specific, addressable point in the patient journey, and the intervention is built around real behavior rather than assumptions.

Prioritizing KOL Engagement for Medical Affairs

A medical-affairs team needs to focus limited resources on the providers who genuinely shape treatment in a therapeutic area. Rather than ranking physicians by prescribing volume alone, they use Komodo's seven-signal KOL profiling to weigh referral influence, network centrality, and clinical activity. The output reorders the priority list, surfacing influential providers who weren't top prescribers and deprioritizing high-volume names with little peer influence. The team builds its engagement and advisory-board strategy around the providers who actually move the field, getting more impact from the same headcount and budget.

Key Features

Claims analytics
Patient journey mapping
KOL identification
Treatment patterns
Market sizing
Provider targeting

Pricing

Plan	Price
Enterprise	Custom pricing only

Pricing as of 2026. Check Komodo Health's website for current pricing.

Pricing Analysis

Komodo Health uses custom enterprise pricing with no published rates and no self-serve option. Reported figures put individual use-case subscriptions in roughly the $150K to $450K per-year range, while licensing the full Healthcare Map dataset plus the analytics suite can reach into the seven figures (industry reporting cites around $2M/yr for full access). Pricing scales with data scope, the number of use cases, user counts, and which analytics products and enrichment layers you include.

That puts Komodo above Definitive Healthcare on average deal size but generally below IQVIA's largest multi-year real-world-data contracts. The model is SaaS-style subscription rather than IQVIA's high-minimum multi-year licensing, which can make Komodo more approachable for specialty and rare-disease biopharma that need maximum completeness on a narrow population rather than the broadest possible coverage. Still, this is six- to seven-figure software, not a tool you trial casually.

For budgeting, plan for a multi-month procurement process and factor in the analyst capacity needed to actually use the platform. The ROI case has to come from better launch decisions, sharper patient-population estimates, and more efficient KOL and field targeting. Teams that can tie those outcomes to real revenue or saved spend have a clear justification; teams that just want provider contact data will find Komodo expensive for the wrong reason and should look at a contact-focused provider instead.

Frequently Asked Questions

What is Komodo Health used for?

Komodo Health is used for claims-based healthcare analytics, especially patient-journey mapping, market sizing, and provider targeting for pharma and life sciences. Its Healthcare Map follows de-identified patients across diagnoses, treatments, and outcomes, drawing on more than 330 million patient records. Teams use it to understand patient populations, find undiagnosed patients, diagnose therapy abandonment, and identify the providers who drive treatment decisions.

Is Komodo Health a contact data provider?

No. Komodo is an analytics platform, not a contact database. It tells you which providers matter and what's happening to patients, but it won't hand you verified emails and cell phones for cold outreach. Most teams pair Komodo's targeting intelligence with a separate contact-data source like Provyx, Definitive Healthcare, or IQVIA OneKey to get the actual reach-out details.

How much does Komodo Health cost?

Komodo uses custom enterprise pricing with no public rates. Reported figures put per-use-case subscriptions in the $150K to $450K per-year range, with full dataset and analytics-suite licensing reaching into the seven figures. Pricing depends on data scope, number of use cases, and which analytics products you include. Expect a multi-month enterprise procurement process rather than a self-serve signup.

How does Komodo Health compare to IQVIA?

Both serve pharma, but they differ in model and strength. IQVIA uses high-minimum multi-year licensing and excels at global coverage and projection-based market measurement for large pharma. Komodo uses SaaS-style subscriptions and emphasizes completeness on US patient journeys, which often makes it better for specialty and rare-disease launches where a small population needs maximum data completeness rather than the broadest reach.

What is the Healthcare Map?

The Healthcare Map is Komodo's core dataset: a de-identified, longitudinal view of more than 330 million US patients built from medical and pharmacy claims across providers and payers. It tracks each patient's encounters over time, so teams can follow journeys from diagnosis through treatment and outcomes. It's the foundation under Komodo's analytics products, KOL profiling, and enrichment tools like MapEnhance and Patient Insights.

Similar Tools

By Rome Thorndike

Reviewed by Rome Thorndike. Last verified 2026-06-03.

Pricing, features, and ratings are based on vendor documentation, public filings, product demos, and feedback from sales teams using these tools in production. We update reviews when vendors ship major releases or change pricing.